Results 91 to 100 of about 40,821 (327)
Drug Design, Development and Therapy, 2016 Thomas J Monaco,1 Carlos D Davila2 1Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, 2Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA Abstract: Pulmonary arterial hypertension is a ...
Monaco TJ, Davila CD
doaj
Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan [PDF]
, 2019 Objectives: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class ...
Gabbay, Eli +3 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr +15 more
wiley +1 more source
Anti-endothelin drugs in solid tumors [PDF]
, 2010 Importance of the field: The endothelin (ET) axis, which includes the biological functions of ETs and their receptors, has played a physiological role in normal tissue, acting as a modulator of vasomotor tone, tissue differentiation and development, cell
Bazan, V. +6 more
core +1 more source
Endothelin‐1 and Endothelin Receptor Antagonists in Cardiovascular Remodeling
Proceedings of the Society for Experimental Biology and Medicine, 1999 Endothelins build a peptide family composed of three isoforms, each of them containing 21 amino acids. Endothelin‐1 is the isoform mainly responsible for any cardiovascular action and therefore the sole scope of this review. Endothelin‐1 is the most potent endogenous vasoconstrictor known; in addition it acts as a potent (co)mitogen.
M, Kirchengast, K, Münter
openaire +2 more sources
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Pediatric intestinal pseudo‐obstruction (PIPO) is a severe bowel motility disorder characterized by impaired propulsion of gastrointestinal contents without mechanical obstruction. PIPO encompasses congenital and acquired disorders, including neuropathies, myopathies, and mesenchymopathies.
Sharon Wolfson +8 more
wiley +1 more source
Pulmonary arterial hypertension: diagnosis and treatment
Studia Medyczne, 2013 Pulmonary arterial hypertension is one of the clinical groups of arterial hypertension. It is a rare, chronic disease with a very poor prognosis.
Marcin Sadowski +4 more
doaj +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa +2 more
wiley +1 more source
Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats [PDF]
, 2014 Background: In this study, the neuroprotective effect of a novel nonpeptide AT2R agonist, C21, was examined in a conscious model of stroke to verify a class effect of AT2R agonists as neuroprotective agents.
Alterman, Mathias +6 more
core +2 more sources
Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]
, 2016 Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A. +1 more
core +2 more sources